Login to Your Account



'Baxter' the Wall: Biogen/Sobi Data Weighed in Hemophilia A

By Randy Osborne
Staff Writer

Wednesday, November 7, 2012
With safety and efficacy endpoints met last week in the Phase III trial testing Biogen Idec Inc.'s long-lasting rFVIIIFc (recombinant Factor VIII Fc fusion protein) for hemophilia A, investors were scrutinizing the candidate's odds in a market led by Advate, the serum-free, recombinant Factor VIII therapy from Baxter Healthcare Corp.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription